Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.

Chun-Yi LuChing-Hu ChungLi-Min HuangEliza KrugerSeng-Chuen TanXu-Hao ZhangNan-Chang Chiu

Published in: Cost effectiveness and resource allocation : C/E (2020)

PHiD-CV 2 + 1 would provide comparable prevention of IPD, pneumonia cases and additional reduction of NTHi-AOM cases, and is considered dominant compared with PCV13 2 + 1 in Taiwan.

Keyphrases

young adults
cancer therapy
binding protein
drug delivery
acute respiratory distress syndrome
extracorporeal membrane oxygenation